• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global IBS-C Drug Market Insights and Forecast to 2026

report cover
  • 31 July 2020
  • Pharmaceuticals
  • 150 Pages
  • Report Code: 24LS-16470
  • Formate :   
Download FREE Report Sample Download PDF File

IBS C Drug -MARKET ADVISORY SERVICES

IBS-C Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global IBS-C Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.


Segment by Type, the IBS-C Drug market is segmented into

  • Linaclotide
  • Lubiprostone
  • Osmotic Laxatives
  • Stimulant Laxatives
  • Other


Segment by Application, the IBS-C Drug market is segmented into

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


Regional and Country-level Analysis
The IBS-C Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the IBS-C Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and IBS-C Drug Market Share Analysis
IBS-C Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in IBS-C Drug business, the date to enter into the IBS-C Drug market, IBS-C Drug product introduction, recent developments, etc.

The major vendors covered:

  • Catalent Pharmaceuticals Solutions
  • Nestle
  • Abbott Laboratories
  • Synergy Pharmaceuticals
  • Sucampo Pharmaceuticals
  • Novartis Pharma
  • Astellas Pharmaceuticals
  • Ardelyx
  • Synthetic Biologics
  • Teva Pharmaceutical Industries
  • Bama-Geve
  • Ferring BV
  • Ironwood Pharmaceuticals
  • Salix Pharmaceuticals
  • Norgine
  • Prometheus Laboratories
  • Actavis Nordic
  • Albireo Pharma
  • Yuhan Corp
  • Astrazeneca
  • The Menarini Group
  • Ono Pharmaceutical
1 Study Coverage
1.1 IBS-C Drug Product Introduction
1.2 Market Segments
1.3 Key IBS-C Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global IBS-C Drug Market Size Growth Rate by Type
1.4.2 Linaclotide
1.4.3 Lubiprostone
1.4.4 Osmotic Laxatives
1.4.5 Stimulant Laxatives
1.4.6 Other
1.5 Market by Application
1.5.1 Global IBS-C Drug Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global IBS-C Drug Market Size, Estimates and Forecasts
2.1.1 Global IBS-C Drug Revenue 2015-2026
2.1.2 Global IBS-C Drug Sales 2015-2026
2.2 Global IBS-C Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global IBS-C Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global IBS-C Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global IBS-C Drug Competitor Landscape by Players
3.1 IBS-C Drug Sales by Manufacturers
3.1.1 IBS-C Drug Sales by Manufacturers (2015-2020)
3.1.2 IBS-C Drug Sales Market Share by Manufacturers (2015-2020)
3.2 IBS-C Drug Revenue by Manufacturers
3.2.1 IBS-C Drug Revenue by Manufacturers (2015-2020)
3.2.2 IBS-C Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global IBS-C Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by IBS-C Drug Revenue in 2019
3.2.5 Global IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 IBS-C Drug Price by Manufacturers
3.4 IBS-C Drug Manufacturing Base Distribution, Product Types
3.4.1 IBS-C Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers IBS-C Drug Product Type
3.4.3 Date of International Manufacturers Enter into IBS-C Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global IBS-C Drug Market Size by Type (2015-2020)
4.1.1 Global IBS-C Drug Sales by Type (2015-2020)
4.1.2 Global IBS-C Drug Revenue by Type (2015-2020)
4.1.3 IBS-C Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global IBS-C Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global IBS-C Drug Sales Forecast by Type (2021-2026)
4.2.2 Global IBS-C Drug Revenue Forecast by Type (2021-2026)
4.2.3 IBS-C Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global IBS-C Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global IBS-C Drug Market Size by Application (2015-2020)
5.1.1 Global IBS-C Drug Sales by Application (2015-2020)
5.1.2 Global IBS-C Drug Revenue by Application (2015-2020)
5.1.3 IBS-C Drug Price by Application (2015-2020)
5.2 IBS-C Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global IBS-C Drug Sales Forecast by Application (2021-2026)
5.2.2 Global IBS-C Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global IBS-C Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America IBS-C Drug by Country
6.1.1 North America IBS-C Drug Sales by Country
6.1.2 North America IBS-C Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America IBS-C Drug Market Facts & Figures by Type
6.3 North America IBS-C Drug Market Facts & Figures by Application

7 Europe
7.1 Europe IBS-C Drug by Country
7.1.1 Europe IBS-C Drug Sales by Country
7.1.2 Europe IBS-C Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe IBS-C Drug Market Facts & Figures by Type
7.3 Europe IBS-C Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific IBS-C Drug by Region
8.1.1 Asia Pacific IBS-C Drug Sales by Region
8.1.2 Asia Pacific IBS-C Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific IBS-C Drug Market Facts & Figures by Type
8.3 Asia Pacific IBS-C Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America IBS-C Drug by Country
9.1.1 Latin America IBS-C Drug Sales by Country
9.1.2 Latin America IBS-C Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America IBS-C Drug Market Facts & Figures by Type
9.3 Central & South America IBS-C Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa IBS-C Drug by Country
10.1.1 Middle East and Africa IBS-C Drug Sales by Country
10.1.2 Middle East and Africa IBS-C Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa IBS-C Drug Market Facts & Figures by Type
10.3 Middle East and Africa IBS-C Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Catalent Pharmaceuticals Solutions
11.1.1 Catalent Pharmaceuticals Solutions Corporation Information
11.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
11.1.3 Catalent Pharmaceuticals Solutions Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
11.1.5 Catalent Pharmaceuticals Solutions Related Developments
11.2 Nestle
11.2.1 Nestle Corporation Information
11.2.2 Nestle Description and Business Overview
11.2.3 Nestle Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Nestle IBS-C Drug Products Offered
11.2.5 Nestle Related Developments
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Corporation Information
11.3.2 Abbott Laboratories Description and Business Overview
11.3.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Abbott Laboratories IBS-C Drug Products Offered
11.3.5 Abbott Laboratories Related Developments
11.4 Synergy Pharmaceuticals
11.4.1 Synergy Pharmaceuticals Corporation Information
11.4.2 Synergy Pharmaceuticals Description and Business Overview
11.4.3 Synergy Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Synergy Pharmaceuticals IBS-C Drug Products Offered
11.4.5 Synergy Pharmaceuticals Related Developments
11.5 Sucampo Pharmaceuticals
11.5.1 Sucampo Pharmaceuticals Corporation Information
11.5.2 Sucampo Pharmaceuticals Description and Business Overview
11.5.3 Sucampo Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Sucampo Pharmaceuticals IBS-C Drug Products Offered
11.5.5 Sucampo Pharmaceuticals Related Developments
11.6 Novartis Pharma
11.6.1 Novartis Pharma Corporation Information
11.6.2 Novartis Pharma Description and Business Overview
11.6.3 Novartis Pharma Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Novartis Pharma IBS-C Drug Products Offered
11.6.5 Novartis Pharma Related Developments
11.7 Astellas Pharmaceuticals
11.7.1 Astellas Pharmaceuticals Corporation Information
11.7.2 Astellas Pharmaceuticals Description and Business Overview
11.7.3 Astellas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Astellas Pharmaceuticals IBS-C Drug Products Offered
11.7.5 Astellas Pharmaceuticals Related Developments
11.8 Ardelyx
11.8.1 Ardelyx Corporation Information
11.8.2 Ardelyx Description and Business Overview
11.8.3 Ardelyx Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Ardelyx IBS-C Drug Products Offered
11.8.5 Ardelyx Related Developments
11.9 Synthetic Biologics
11.9.1 Synthetic Biologics Corporation Information
11.9.2 Synthetic Biologics Description and Business Overview
11.9.3 Synthetic Biologics Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Synthetic Biologics IBS-C Drug Products Offered
11.9.5 Synthetic Biologics Related Developments
11.10 Teva Pharmaceutical Industries
11.10.1 Teva Pharmaceutical Industries Corporation Information
11.10.2 Teva Pharmaceutical Industries Description and Business Overview
11.10.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Teva Pharmaceutical Industries IBS-C Drug Products Offered
11.10.5 Teva Pharmaceutical Industries Related Developments
11.1 Catalent Pharmaceuticals Solutions
11.1.1 Catalent Pharmaceuticals Solutions Corporation Information
11.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
11.1.3 Catalent Pharmaceuticals Solutions Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
11.1.5 Catalent Pharmaceuticals Solutions Related Developments
11.12 Ferring BV
11.12.1 Ferring BV Corporation Information
11.12.2 Ferring BV Description and Business Overview
11.12.3 Ferring BV Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Ferring BV Products Offered
11.12.5 Ferring BV Related Developments
11.13 Ironwood Pharmaceuticals
11.13.1 Ironwood Pharmaceuticals Corporation Information
11.13.2 Ironwood Pharmaceuticals Description and Business Overview
11.13.3 Ironwood Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Ironwood Pharmaceuticals Products Offered
11.13.5 Ironwood Pharmaceuticals Related Developments
11.14 Salix Pharmaceuticals
11.14.1 Salix Pharmaceuticals Corporation Information
11.14.2 Salix Pharmaceuticals Description and Business Overview
11.14.3 Salix Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Salix Pharmaceuticals Products Offered
11.14.5 Salix Pharmaceuticals Related Developments
11.15 Norgine
11.15.1 Norgine Corporation Information
11.15.2 Norgine Description and Business Overview
11.15.3 Norgine Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Norgine Products Offered
11.15.5 Norgine Related Developments
11.16 Prometheus Laboratories
11.16.1 Prometheus Laboratories Corporation Information
11.16.2 Prometheus Laboratories Description and Business Overview
11.16.3 Prometheus Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Prometheus Laboratories Products Offered
11.16.5 Prometheus Laboratories Related Developments
11.17 Actavis Nordic
11.17.1 Actavis Nordic Corporation Information
11.17.2 Actavis Nordic Description and Business Overview
11.17.3 Actavis Nordic Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Actavis Nordic Products Offered
11.17.5 Actavis Nordic Related Developments
11.18 Albireo Pharma
11.18.1 Albireo Pharma Corporation Information
11.18.2 Albireo Pharma Description and Business Overview
11.18.3 Albireo Pharma Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Albireo Pharma Products Offered
11.18.5 Albireo Pharma Related Developments
11.19 Yuhan Corp
11.19.1 Yuhan Corp Corporation Information
11.19.2 Yuhan Corp Description and Business Overview
11.19.3 Yuhan Corp Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Yuhan Corp Products Offered
11.19.5 Yuhan Corp Related Developments
11.20 Astrazeneca
11.20.1 Astrazeneca Corporation Information
11.20.2 Astrazeneca Description and Business Overview
11.20.3 Astrazeneca Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Astrazeneca Products Offered
11.20.5 Astrazeneca Related Developments
11.21 The Menarini Group
11.21.1 The Menarini Group Corporation Information
11.21.2 The Menarini Group Description and Business Overview
11.21.3 The Menarini Group Sales, Revenue and Gross Margin (2015-2020)
11.21.4 The Menarini Group Products Offered
11.21.5 The Menarini Group Related Developments
11.22 Ono Pharmaceutical
11.22.1 Ono Pharmaceutical Corporation Information
11.22.2 Ono Pharmaceutical Description and Business Overview
11.22.3 Ono Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Ono Pharmaceutical Products Offered
11.22.5 Ono Pharmaceutical Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 IBS-C Drug Market Estimates and Projections by Region
12.1.1 Global IBS-C Drug Sales Forecast by Regions 2021-2026
12.1.2 Global IBS-C Drug Revenue Forecast by Regions 2021-2026
12.2 North America IBS-C Drug Market Size Forecast (2021-2026)
12.2.1 North America: IBS-C Drug Sales Forecast (2021-2026)
12.2.2 North America: IBS-C Drug Revenue Forecast (2021-2026)
12.2.3 North America: IBS-C Drug Market Size Forecast by Country (2021-2026)
12.3 Europe IBS-C Drug Market Size Forecast (2021-2026)
12.3.1 Europe: IBS-C Drug Sales Forecast (2021-2026)
12.3.2 Europe: IBS-C Drug Revenue Forecast (2021-2026)
12.3.3 Europe: IBS-C Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific IBS-C Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: IBS-C Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: IBS-C Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: IBS-C Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America IBS-C Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: IBS-C Drug Sales Forecast (2021-2026)
12.5.2 Latin America: IBS-C Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: IBS-C Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa IBS-C Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: IBS-C Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: IBS-C Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: IBS-C Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key IBS-C Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 IBS-C Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables

Table 1. IBS-C Drug Market Segments

Table 2. Ranking of Global Top IBS-C Drug Manufacturers by Revenue (US$ Million) in 2019

Table 3. Global IBS-C Drug Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)

Table 4. Major Manufacturers of Linaclotide

Table 5. Major Manufacturers of Lubiprostone

Table 6. Major Manufacturers of Osmotic Laxatives

Table 7. Major Manufacturers of Stimulant Laxatives

Table 8. Major Manufacturers of Other

Table 9. Global IBS-C Drug Market Size Growth Rate by Application 2020-2026 (K Units)

Table 10. Global IBS-C Drug Market Size by Region (K Units) & (US$ Million): 2020 VS 2026

Table 11. Global IBS-C Drug Sales by Regions 2015-2020 (K Units)

Table 12. Global IBS-C Drug Sales Market Share by Regions (2015-2020)

Table 13. Global IBS-C Drug Revenue by Regions 2015-2020 (US$ Million)

Table 14. Global IBS-C Drug Sales by Manufacturers (2015-2020) (K Units)

Table 15. Global IBS-C Drug Sales Share by Manufacturers (2015-2020)

Table 16. Global IBS-C Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 17. Global IBS-C Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS-C Drug as of 2019)

Table 18. IBS-C Drug Revenue by Manufacturers (2015-2020) (US$ Million)

Table 19. IBS-C Drug Revenue Share by Manufacturers (2015-2020)

Table 20. Key Manufacturers IBS-C Drug Price (2015-2020) (USD/Unit)

Table 21. IBS-C Drug Manufacturers Manufacturing Base Distribution and Headquarters

Table 22. Manufacturers IBS-C Drug Product Type

Table 23. Date of International Manufacturers Enter into IBS-C Drug Market

Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 25. Global IBS-C Drug Sales by Type (2015-2020) (K Units)

Table 26. Global IBS-C Drug Sales Share by Type (2015-2020)

Table 27. Global IBS-C Drug Revenue by Type (2015-2020) (US$ Million)

Table 28. Global IBS-C Drug Revenue Share by Type (2015-2020)

Table 29. IBS-C Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)

Table 30. Global IBS-C Drug Sales by Application (2015-2020) (K Units)

Table 31. Global IBS-C Drug Sales Share by Application (2015-2020)

Table 32. North America IBS-C Drug Sales by Country (2015-2020) (K Units)

Table 33. North America IBS-C Drug Sales Market Share by Country (2015-2020)

Table 34. North America IBS-C Drug Revenue by Country (2015-2020) (US$ Million)

Table 35. North America IBS-C Drug Revenue Market Share by Country (2015-2020)

Table 36. North America IBS-C Drug Sales by Type (2015-2020) (K Units)

Table 37. North America IBS-C Drug Sales Market Share by Type (2015-2020)

Table 38. North America IBS-C Drug Sales by Application (2015-2020) (K Units)

Table 39. North America IBS-C Drug Sales Market Share by Application (2015-2020)

Table 40. Europe IBS-C Drug Sales by Country (2015-2020) (K Units)

Table 41. Europe IBS-C Drug Sales Market Share by Country (2015-2020)

Table 42. Europe IBS-C Drug Revenue by Country (2015-2020) (US$ Million)

Table 43. Europe IBS-C Drug Revenue Market Share by Country (2015-2020)

Table 44. Europe IBS-C Drug Sales by Type (2015-2020) (K Units)

Table 45. Europe IBS-C Drug Sales Market Share by Type (2015-2020)

Table 46. Europe IBS-C Drug Sales by Application (2015-2020) (K Units)

Table 47. Europe IBS-C Drug Sales Market Share by Application (2015-2020)

Table 48. Asia Pacific IBS-C Drug Sales by Region (2015-2020) (K Units)

Table 49. Asia Pacific IBS-C Drug Sales Market Share by Region (2015-2020)

Table 50. Asia Pacific IBS-C Drug Revenue by Region (2015-2020) (US$ Million)

Table 51. Asia Pacific IBS-C Drug Revenue Market Share by Region (2015-2020)

Table 52. Asia Pacific IBS-C Drug Sales by Type (2015-2020) (K Units)

Table 53. Asia Pacific IBS-C Drug Sales Market Share by Type (2015-2020)

Table 54. Asia Pacific IBS-C Drug Sales by Application (2015-2020) (K Units)

Table 55. Asia Pacific IBS-C Drug Sales Market Share by Application (2015-2020)

Table 56. Latin America IBS-C Drug Sales by Country (2015-2020) (K Units)

Table 57. Latin America IBS-C Drug Sales Market Share by Country (2015-2020)

Table 58. Latin Americaa IBS-C Drug Revenue by Country (2015-2020) (US$ Million)

Table 59. Latin America IBS-C Drug Revenue Market Share by Country (2015-2020)

Table 60. Latin America IBS-C Drug Sales by Type (2015-2020) (K Units)

Table 61. Latin America IBS-C Drug Sales Market Share by Type (2015-2020)

Table 62. Latin America IBS-C Drug Sales by Application (2015-2020) (K Units)

Table 63. Latin America IBS-C Drug Sales Market Share by Application (2015-2020)

Table 64. Middle East and Africa IBS-C Drug Sales by Country (2015-2020) (K Units)

Table 65. Middle East and Africa IBS-C Drug Sales Market Share by Country (2015-2020)

Table 66. Middle East and Africa IBS-C Drug Revenue by Country (2015-2020) (US$ Million)

Table 67. Middle East and Africa IBS-C Drug Revenue Market Share by Country (2015-2020)

Table 68. Middle East and Africa IBS-C Drug Sales by Type (2015-2020) (K Units)

Table 69. Middle East and Africa IBS-C Drug Sales Market Share by Type (2015-2020)

Table 70. Middle East and Africa IBS-C Drug Sales by Application (2015-2020) (K Units)

Table 71. Middle East and Africa IBS-C Drug Sales Market Share by Application (2015-2020)

Table 72. Catalent Pharmaceuticals Solutions Corporation Information

Table 73. Catalent Pharmaceuticals Solutions Description and Major Businesses

Table 74. Catalent Pharmaceuticals Solutions IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 75. Catalent Pharmaceuticals Solutions Product

Table 76. Catalent Pharmaceuticals Solutions Recent Development

Table 77. Nestle Corporation Information

Table 78. Nestle Description and Major Businesses

Table 79. Nestle IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 80. Nestle Product

Table 81. Nestle Recent Development

Table 82. Abbott Laboratories Corporation Information

Table 83. Abbott Laboratories Description and Major Businesses

Table 84. Abbott Laboratories IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 85. Abbott Laboratories Product

Table 86. Abbott Laboratories Recent Development

Table 87. Synergy Pharmaceuticals Corporation Information

Table 88. Synergy Pharmaceuticals Description and Major Businesses

Table 89. Synergy Pharmaceuticals IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 90. Synergy Pharmaceuticals Product

Table 91. Synergy Pharmaceuticals Recent Development

Table 92. Sucampo Pharmaceuticals Corporation Information

Table 93. Sucampo Pharmaceuticals Description and Major Businesses

Table 94. Sucampo Pharmaceuticals IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 95. Sucampo Pharmaceuticals Product

Table 96. Sucampo Pharmaceuticals Recent Development

Table 97. Novartis Pharma Corporation Information

Table 98. Novartis Pharma Description and Major Businesses

Table 99. Novartis Pharma IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 100. Novartis Pharma Product

Table 101. Novartis Pharma Recent Development

Table 102. Astellas Pharmaceuticals Corporation Information

Table 103. Astellas Pharmaceuticals Description and Major Businesses

Table 104. Astellas Pharmaceuticals IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 105. Astellas Pharmaceuticals Product

Table 106. Astellas Pharmaceuticals Recent Development

Table 107. Ardelyx Corporation Information

Table 108. Ardelyx Description and Major Businesses

Table 109. Ardelyx IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 110. Ardelyx Product

Table 111. Ardelyx Recent Development

Table 112. Synthetic Biologics Corporation Information

Table 113. Synthetic Biologics Description and Major Businesses

Table 114. Synthetic Biologics IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 115. Synthetic Biologics Product

Table 116. Synthetic Biologics Recent Development

Table 117. Teva Pharmaceutical Industries Corporation Information

Table 118. Teva Pharmaceutical Industries Description and Major Businesses

Table 119. Teva Pharmaceutical Industries IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 120. Teva Pharmaceutical Industries Product

Table 121. Teva Pharmaceutical Industries Recent Development

Table 122. Bama-Geve Corporation Information

Table 123. Bama-Geve Description and Major Businesses

Table 124. Bama-Geve IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 125. Bama-Geve Product

Table 126. Bama-Geve Recent Development

Table 127. Ferring BV Corporation Information

Table 128. Ferring BV Description and Major Businesses

Table 129. Ferring BV IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 130. Ferring BV Product

Table 131. Ferring BV Recent Development

Table 132. Ironwood Pharmaceuticals Corporation Information

Table 133. Ironwood Pharmaceuticals Description and Major Businesses

Table 134. Ironwood Pharmaceuticals IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 135. Ironwood Pharmaceuticals Product

Table 136. Ironwood Pharmaceuticals Recent Development

Table 137. Salix Pharmaceuticals Corporation Information

Table 138. Salix Pharmaceuticals Description and Major Businesses

Table 139. Salix Pharmaceuticals IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 140. Salix Pharmaceuticals Product

Table 141. Salix Pharmaceuticals Recent Development

Table 142. Norgine Corporation Information

Table 143. Norgine Description and Major Businesses

Table 144. Norgine IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 145. Norgine Product

Table 146. Norgine Recent Development

Table 147. Prometheus Laboratories Corporation Information

Table 148. Prometheus Laboratories Description and Major Businesses

Table 149. Prometheus Laboratories IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 150. Prometheus Laboratories Product

Table 151. Prometheus Laboratories Recent Development

Table 152. Actavis Nordic Corporation Information

Table 153. Actavis Nordic Description and Major Businesses

Table 154. Actavis Nordic IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 155. Actavis Nordic Product

Table 156. Actavis Nordic Recent Development

Table 157. Albireo Pharma Corporation Information

Table 158. Albireo Pharma Description and Major Businesses

Table 159. Albireo Pharma IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 160. Albireo Pharma Product

Table 161. Albireo Pharma Recent Development

Table 162. Yuhan Corp Corporation Information

Table 163. Yuhan Corp Description and Major Businesses

Table 164. Yuhan Corp IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 165. Yuhan Corp Product

Table 166. Yuhan Corp Recent Development

Table 167. Astrazeneca Corporation Information

Table 168. Astrazeneca Description and Major Businesses

Table 169. Astrazeneca IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 170. Astrazeneca Product

Table 171. Astrazeneca Recent Development

Table 172. The Menarini Group Corporation Information

Table 173. The Menarini Group Description and Major Businesses

Table 174. The Menarini Group IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 175. The Menarini Group Product

Table 176. The Menarini Group Recent Development

Table 177. Ono Pharmaceutical Corporation Information

Table 178. Ono Pharmaceutical Description and Major Businesses

Table 179. Ono Pharmaceutical IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 180. Ono Pharmaceutical Product

Table 181. Ono Pharmaceutical Recent Development

Table 182. Global IBS-C Drug Sales Forecast by Regions (2021-2026) (K Units)

Table 183. Global IBS-C Drug Sales Market Share Forecast by Regions (2021-2026)

Table 184. Global IBS-C Drug Revenue Forecast by Regions (2021-2026) (US$ Million)

Table 185. Global IBS-C Drug Revenue Market Share Forecast by Regions (2021-2026)

Table 186. North America: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)

Table 187. North America: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)

Table 188. Europe: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)

Table 189. Europe: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)

Table 190. Asia Pacific: IBS-C Drug Sales Forecast by Region (2021-2026) (K Units)

Table 191. Asia Pacific: IBS-C Drug Revenue Forecast by Region (2021-2026) (US$ Million)

Table 192. Latin America: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)

Table 193. Latin America: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)

Table 194. Middle East and Africa: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)

Table 195. Middle East and Africa: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)

Table 196. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 197. Key Challenges

Table 198. Market Risks

Table 199. Main Points Interviewed from Key IBS-C Drug Players

Table 200. IBS-C Drug Customers List

Table 201. IBS-C Drug Distributors List

Table 202. Research Programs/Design for This Report

Table 203. Key Data Information from Secondary Sources

Table 204. Key Data Information from Primary Sources

List of Figures

Figure 1. IBS-C Drug Product Picture

Figure 2. Global IBS-C Drug Sales Market Share by Type in 2020 & 2026

Figure 3. Linaclotide Product Picture

Figure 4. Lubiprostone Product Picture

Figure 5. Osmotic Laxatives Product Picture

Figure 6. Stimulant Laxatives Product Picture

Figure 7. Other Product Picture

Figure 8. Global IBS-C Drug Sales Market Share by Application in 2020 & 2026

Figure 9. Hospital Pharmacies

Figure 10. Retail Pharmacies

Figure 11. Online Pharmacies

Figure 12. IBS-C Drug Report Years Considered

Figure 13. Global IBS-C Drug Market Size 2015-2026 (US$ Million)

Figure 14. Global IBS-C Drug Sales 2015-2026 (K Units)

Figure 15. Global IBS-C Drug Market Size Market Share by Region: 2020 Versus 2026

Figure 16. Global IBS-C Drug Sales Market Share by Region (2015-2020)

Figure 17. Global IBS-C Drug Sales Market Share by Region in 2019

Figure 18. Global IBS-C Drug Revenue Market Share by Region (2015-2020)

Figure 19. Global IBS-C Drug Revenue Market Share by Region in 2019

Figure 20. Global IBS-C Drug Sales Share by Manufacturer in 2019

Figure 21. The Top 10 and 5 Players Market Share by IBS-C Drug Revenue in 2019

Figure 22. IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 23. Global IBS-C Drug Sales Market Share by Type (2015-2020)

Figure 24. Global IBS-C Drug Sales Market Share by Type in 2019

Figure 25. Global IBS-C Drug Revenue Market Share by Type (2015-2020)

Figure 26. Global IBS-C Drug Revenue Market Share by Type in 2019

Figure 27. Global IBS-C Drug Market Share by Price Range (2015-2020)

Figure 28. Global IBS-C Drug Sales Market Share by Application (2015-2020)

Figure 29. Global IBS-C Drug Sales Market Share by Application in 2019

Figure 30. Global IBS-C Drug Revenue Market Share by Application (2015-2020)

Figure 31. Global IBS-C Drug Revenue Market Share by Application in 2019

Figure 32. North America IBS-C Drug Sales Growth Rate 2015-2020 (K Units)

Figure 33. North America IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)

Figure 34. North America IBS-C Drug Sales Market Share by Country in 2019

Figure 35. North America IBS-C Drug Revenue Market Share by Country in 2019

Figure 36. U.S. IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 37. U.S. IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 38. Canada IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 39. Canada IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 40. North America IBS-C Drug Market Share by Type in 2019

Figure 41. North America IBS-C Drug Market Share by Application in 2019

Figure 42. Europe IBS-C Drug Sales Growth Rate 2015-2020 (K Units)

Figure 43. Europe IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)

Figure 44. Europe IBS-C Drug Sales Market Share by Country in 2019

Figure 45. Europe IBS-C Drug Revenue Market Share by Country in 2019

Figure 46. Germany IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 47. Germany IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 48. France IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 49. France IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 50. U.K. IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 51. U.K. IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 52. Italy IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 53. Italy IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 54. Russia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 55. Russia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 56. Europe IBS-C Drug Market Share by Type in 2019

Figure 57. Europe IBS-C Drug Market Share by Application in 2019

Figure 58. Asia Pacific IBS-C Drug Sales Growth Rate 2015-2020 (K Units)

Figure 59. Asia Pacific IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)

Figure 60. Asia Pacific IBS-C Drug Sales Market Share by Region in 2019

Figure 61. Asia Pacific IBS-C Drug Revenue Market Share by Region in 2019

Figure 62. China IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 63. China IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 64. Japan IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 65. Japan IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 66. South Korea IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 67. South Korea IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 68. India IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 69. India IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 70. Australia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 71. Australia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 72. Taiwan IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 73. Taiwan IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 74. Indonesia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 75. Indonesia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 76. Thailand IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 77. Thailand IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 78. Malaysia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 79. Malaysia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 80. Philippines IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 81. Philippines IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 82. Vietnam IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 83. Vietnam IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 84. Asia Pacific IBS-C Drug Market Share by Type in 2019

Figure 85. Asia Pacific IBS-C Drug Market Share by Application in 2019

Figure 86. Latin America IBS-C Drug Sales Growth Rate 2015-2020 (K Units)

Figure 87. Latin America IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)

Figure 88. Latin America IBS-C Drug Sales Market Share by Country in 2019

Figure 89. Latin America IBS-C Drug Revenue Market Share by Country in 2019

Figure 90. Mexico IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 91. Mexico IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 92. Brazil IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 93. Brazil IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 94. Argentina IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 95. Argentina IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 96. Latin America IBS-C Drug Market Share by Type in 2019

Figure 97. Latin America IBS-C Drug Market Share by Application in 2019

Figure 98. Middle East and Africa IBS-C Drug Sales Growth Rate 2015-2020 (K Units)

Figure 99. Middle East and Africa IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)

Figure 100. Middle East and Africa IBS-C Drug Sales Market Share by Country in 2019

Figure 101. Middle East and Africa IBS-C Drug Revenue Market Share by Country in 2019

Figure 102. Turkey IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 103. Turkey IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 104. Saudi Arabia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 105. Saudi Arabia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 106. U.A.E IBS-C Drug Sales Growth Rate (2015-2020) (K Units)

Figure 107. U.A.E IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)

Figure 108. Middle East and Africa IBS-C Drug Market Share by Type in 2019

Figure 109. Middle East and Africa IBS-C Drug Market Share by Application in 2019

Figure 110. North America IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 111. North America IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 112. Europe IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 113. Europe IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 114. Asia Pacific IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 115. Asia Pacific IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 116. Latin America IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 117. Latin America IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 118. Middle East and Africa IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 119. Middle East and Africa IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 120. Porter's Five Forces Analysis

Figure 121. Channels of Distribution

Figure 122. Distributors Profiles

Figure 123. Bottom-up and Top-down Approaches for This Report

Figure 124. Data Triangulation

Figure 125. Key Executives Interviewed

Catalent Pharmaceuticals Solutions

Nestle

Abbott Laboratories

Synergy Pharmaceuticals

Sucampo Pharmaceuticals

Novartis Pharma

Astellas Pharmaceuticals

Ardelyx

Synthetic Biologics

Teva Pharmaceutical Industries

Bama-Geve

Ferring BV

Ironwood Pharmaceuticals

Salix Pharmaceuticals

Norgine

Prometheus Laboratories

Actavis Nordic

Albireo Pharma

Yuhan Corp

Astrazeneca

The Menarini Group

Ono Pharmaceutical

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $3315

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase